Investigating delays in treatment for heart attack patients
The Impact of Pre-Hospital and Hospital Delays on Myocardial Infarction Outcomes: A Prospective Study
This study looks at how delays in treatment for heart attack patients affect their recovery and survival to see if we can find ways to help them do better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Al-Nahrain University Academic / other |
| Locations | 1 site (Baghdad) |
| Trial ID | NCT06738498 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how delays before and during hospital treatment affect outcomes for patients experiencing a myocardial infarction (MI). It will track the time from symptom onset to first medical contact and subsequent hospital care, analyzing how these delays influence mortality rates, complications, and recovery times. The study will be conducted at Al-Kadhimiya Teaching Hospital in Baghdad, focusing on patients who receive reperfusion therapy within 12 hours of symptom onset. By understanding these delays, the study hopes to identify factors that can be targeted to improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients who consent to participate and are admitted to the hospital for reperfusion therapy within 12 hours of experiencing MI symptoms.
Not a fit: Patients with non-acute myocardial infarction or severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for reducing treatment delays, ultimately enhancing survival rates and recovery for heart attack patients.
How similar studies have performed: Previous studies have shown that addressing treatment delays can significantly improve outcomes for myocardial infarction patients, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who provide informed consent (or a legal representative provides consent if the patient is unable to do so). * Patients who undergo reperfusion therapy, such as thrombolysis or percutaneous coronary intervention (PCI). * Patients admitted to Al-Kadhimiya Teaching Hospital within 12 hours of symptom onset. Exclusion Criteria: * Patients with non-acute myocardial infarction (e.g., stable angina, prior MI). * Patients with severe comorbidities (e.g., advanced cancer, end-stage renal disease) that may complicate outcome assessments or interfere with treatment protocols. * Patients who are transferred to another facility before reperfusion therapy is initiated. * Pregnant women or breastfeeding women.
Where this trial is running
Baghdad
- College of Medicine - Al-Nahrain University — Baghdad, Iraq (Recruiting)
Study contacts
- Study coordinator: Abdulillah R. Khamees
- Email: allaabed987@ced.nahrainuniv.edu.iq
- Phone: +9647838571013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.